A Study of the Safety and Effectiveness of NEOD001 for Treating Previously Treated Patients with Persistent Cardiac Dysfunction Related to Light Chain Amyloidosis

Overview

About this study

The purpose of this study is to assess the effectiveness and safety of NEOD001 administered intravenously in adults with light chain amyloidosis who have had a hematologic response to previous treatment for their amyloidosis (e.g., chemotherapy, autologous stem cell transplant [ASCT]) and have persistent cardiac dysfunction.

Participation eligibility

Participant eligibility includes age, gender, type and stage of disease, and previous treatments or health concerns. Guidelines differ from study to study, and identify who can or cannot participate. There is no guarantee that every individual who qualifies and wants to participate in a trial will be enrolled. Contact the study team to discuss study eligibility and potential participation.

Inclusion Criteria

  • Age ≥18 years
  • Confirmed diagnosis of systemic AL amyloidosis
  • ≥1 prior systemic plasma cell dyscrasia therapy with at least a partial hematologic response
  • Cardiac involvement
  • NT-proBNP ≥650

Exclusion Criteria

  • Non-AL amyloidosis
  • Meets the International Myeloma Working Group (IMWG) definition of Multiple Myeloma
  • NT-proBNP >5000
  • Received Plasma cell directed chemotherapy within 6 months
  • Received autologous stem cell transplant (ASCT) within 12 months

Participating Mayo Clinic locations

Study statuses change often. Please contact the study team for the most up-to-date information regarding possible participation.

Mayo Clinic Location Status Contact

Jacksonville, Fla.

Mayo Clinic principal investigator

Taimur Sher, M.B.B.S., M.D.

Closed for enrollment

Contact information:

Cancer Center Clinical Trials Referral Office

855-776-0015

Rochester, Minn.

Mayo Clinic principal investigator

Morie Gertz, M.D.

Closed for enrollment

Contact information:

Cancer Center Clinical Trials Referral Office

855-776-0015

More information

Publications

Publications are currently not available